Molecular interaction of human brain acetylcholinesterase with a natural inhibitor Huperzine-B: An enzoinformatics approach

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 487-490

  Alam, Aftab ^a   Shaikh, Sibhghatulla ^a   Ahmad, Syed S ^a   Ansari, Mohammad A ^a   Shakil, Shahnawaz ^b   Rizvi, Syed M D ^a   Shakil, Shazi ^a   Imran, Mohammad ^a   Haneef, Mohammad ^a   Abuzenadah, Adel M ^c   Kamal, Mohammad A ^c  

^a INTEGRAL UNIVERSITY   (India)

^b CARDINAL HEALTH   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Acetylcholinesterase; Autodock4.2; Catalytic site; Hydrophobic interactions

Indexed keywords

CHOLINESTERASE INHIBITOR; HUPERZINE B; ACETYLCHOLINESTERASE; ALKALOID;

ARTICLE; BINDING AFFINITY; BIOINFORMATICS; COMPUTER ANALYSIS; GENETIC ALGORITHM; HYDROGEN BOND; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; MOLECULAR DOCKING; MOLECULAR INTERACTION; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PROTEIN DATABASE; STATISTICS AND NUMERICAL DATA;

ACETYLCHOLINESTERASE; ALKALOIDS; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DATABASES, PROTEIN; HUMANS; MODELS, MOLECULAR;

EID: 84904515470     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660163     Document Type: Article

References (20)

1. Silman I, Sussman JL. Acetylcholinesterase: How is structure related to function? Chem Biol Interact 2008; 175(1-3): 3-10.
2. Darvesh, S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4(2): 131-8.
3. Silman I, Sussman JL. Acetylcholinesterase: 'classical' and 'nonclassical' functions and pharmacology. Curr Opin Pharmacol 2005; 5(3): 293-302
4. Goodsell D. Acetylcholinesterase. Web log post. RCSB Protein Data Bank, June 2004. 04 March, 2013.
5. Munoz-Delgado E, Montenegro MF, Campoy FJ, et al. Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types. FEBS J 2010; 277(21): 4519-29.
6. Howland RH. Alternative drug therapies for dementia. J Psychosocial Nurs Ment Health Serv 2011; 49(5): 17-20.
7. Shi YF, Zhang HY, Wang W, et al. Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors. Acta Pharmacol Sin 2009; 30(8): 1195-203.
8. Liu J, Zhang HY, Wang LM, Tang XC. Inhibitory effects of huperzine B on cholinesterase activity in mice. Acta Pharmacol Sin 1999; 20: 141-5.
9. Wang ZF, Zhou J, Tang XC. Huperzine B protects rat pheochromocytoma cells against oxygen-glucose deprivationinduced injury. Acta Pharmacol Sin 2002; 23: 1193-8.
10. Wu BG, Bai DL. The First Total Synthesis of (±)-Huperzine B. J Org Chem 1997; 62: 5978-81.
11. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem 1996; 271: 23646-9.
12. Munoz-Ruiz P, Rubio L, Garcia-Palomero E, et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem 2005; 48(23): 7223-33.
13. Mehta M, Adem A, Sabbagh M. New Acetylcholinesterase Inhibitors for Alzheimer's Disease. Int J Alzheimers Dis 2012; 2012: 728983.
14. Orhan G, Orhan I, Oztekin-Subutay N, AK F, Sener B. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer's disease. Rec Patents CNS Drug Discov 2009; 4(1): 43-51.
15. Xu Y, Colletier JP, Weik M, et al. Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys J 2008; 95(5): 2500-11.
16. Shakil S, Khan AU. Interaction of 2009 CTX-M variants with drugs and inhibitors: a molecular modelling and docking study. J Proteom Bioinform 2010; 3: 130-4.
17. Sathasivam S. Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag 2011; 7: 313-23.
18. Sun MK, Alkon DL. Links between Alzheimer's disease and diabetes. Drugs Today 2006; 42: 481-9.
19. Shakil S, Khan R, Tabrez S, et al. Interaction of human brain acetylcholinesterase with cyclophosphamide: a molecular modelling and docking study. CNS Neurol Disord Drug Targets 2011; 10: 845-8.
20. Shakil S, Kamal MA, Tabrez S, et al. Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study. CNS Neurol Disord Drug Targets 2012; 11: 142-7.